Literature DB >> 23359498

Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.

Zhi Li1, Milica Gakovic, Josiane Ragimbeau, Maija-Leena Eloranta, Lars Rönnblom, Frédérique Michel, Sandra Pellegrini.   

Abstract

Tyk2 belongs to the Janus protein tyrosine kinase family and is involved in signaling of immunoregulatory cytokines (type I and III IFNs, IL-6, IL-10, and IL-12 families) via its interaction with shared receptor subunits. Depending on the receptor complex, Tyk2 is coactivated with either Jak1 or Jak2, but a detailed molecular characterization of the interplay between the two enzymes is missing. In human populations, the Tyk2 gene presents high levels of genetic diversity with >100 nonsynonymous variants being detected. In this study, we characterized two rare Tyk2 variants, I684S and P1104A, which have been associated with susceptibility to autoimmune disease. Specifically, we measured their in vitro catalytic activity and their ability to mediate Stat activation in fibroblasts and genotyped B cell lines. Both variants were found to be catalytically impaired but rescued signaling in response to IFN-α/β, IL-6, and IL-10. These data, coupled with functional study of an engineered Jak1 P1084A, support a model of nonhierarchical activation of Janus kinases in which one catalytically competent Jak is sufficient for signaling provided that its partner behaves as proper scaffold, even if inactive. Through the analysis of IFN-α and IFN-γ signaling in cells with different Jak1 P1084A levels, we also illustrate a context in which a hypomorphic Jak can hamper signaling in a cytokine-specific manner. Given the multitude of Tyk2-activating cytokines, the cell context-dependent requirement for Tyk2 and the catalytic defect of the two disease-associated variants studied in this paper, we predict that these alleles are functionally significant in complex immune disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359498     DOI: 10.4049/jimmunol.1203118

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Authors:  Xiaoshan Min; Daniela Ungureanu; Sarah Maxwell; Henrik Hammarén; Steve Thibault; Ellin-Kristina Hillert; Merrill Ayres; Brad Greenfield; John Eksterowicz; Chris Gabel; Nigel Walker; Olli Silvennoinen; Zhulun Wang
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

Review 2.  Janus kinases to jakinibs: from basic insights to clinical practice.

Authors:  Massimo Gadina; Mimi T Le; Daniella M Schwartz; Olli Silvennoinen; Shingo Nakayamada; Kunihiro Yamaoka; John J O'Shea
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

3.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

4.  Kinase Inactive Tyrosine Kinase (Tyk2) Supports Differentiation of Brown Fat Cells.

Authors:  Vidisha Raje; Marta Derecka; Marc Cantwell; Jeremy Meier; Karol Szczepanek; Jennifer D Sisler; Birgit Strobl; Ana Gamero; Thurl E Harris; Andrew C Larner
Journal:  Endocrinology       Date:  2017-01-01       Impact factor: 4.736

Review 5.  Genetic overlap between type 1 diabetes and other autoimmune diseases.

Authors:  Ana Márquez; Javier Martín
Journal:  Semin Immunopathol       Date:  2021-10-01       Impact factor: 9.623

6.  Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

Authors:  Elena López-Isac; Diana Campillo-Davo; Lara Bossini-Castillo; Sandra G Guerra; Shervin Assassi; Carmen Pilar Simeón; Patricia Carreira; Norberto Ortego-Centeno; Paloma García de la Peña; Lorenzo Beretta; Alessandro Santaniello; Chiara Bellocchi; Claudio Lunardi; Gianluca Moroncini; Armando Gabrielli; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg Hw Distler; Alexandre E Voskuyl; Jeska de Vries-Bouwstra; Ariane Herrick; Jane Worthington; Christopher P Denton; Carmen Fonseca; Timothy Rdj Radstake; Maureen D Mayes; Javier Martín
Journal:  Ann Rheum Dis       Date:  2015-09-02       Impact factor: 19.103

7.  A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.

Authors:  Sue J Sohn; Kathy Barrett; Anne Van Abbema; Christine Chang; Pawan Bir Kohli; Hidenobu Kanda; Janice Smith; Yingjie Lai; Aihe Zhou; Birong Zhang; Wenqian Yang; Karen Williams; Calum Macleod; Christopher A Hurley; Janusz J Kulagowski; Nicholas Lewin-Koh; Hart S Dengler; Adam R Johnson; Nico Ghilardi; Mark Zak; Jun Liang; Wade S Blair; Steven Magnuson; Lawren C Wu
Journal:  J Immunol       Date:  2013-07-26       Impact factor: 5.422

8.  Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.

Authors:  Calliope A Dendrou; Adrian Cortes; Lydia Shipman; Hayley G Evans; Kathrine E Attfield; Luke Jostins; Thomas Barber; Gurman Kaur; Subita Balaram Kuttikkatte; Oliver A Leach; Christiane Desel; Soren L Faergeman; Jane Cheeseman; Matt J Neville; Stephen Sawcer; Alastair Compston; Adam R Johnson; Christine Everett; John I Bell; Fredrik Karpe; Mark Ultsch; Charles Eigenbrot; Gil McVean; Lars Fugger
Journal:  Sci Transl Med       Date:  2016-11-02       Impact factor: 17.956

Review 9.  Immune diseases caused by mutations in kinases and components of the ubiquitin system.

Authors:  Philip Cohen
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

Review 10.  From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.

Authors:  Dominika Hromadová; Dirk Elewaut; Robert D Inman; Birgit Strobl; Eric Gracey
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.